Tharimmune (THAR)

• Market cap: $108M
• 1 day: -3.13%
• 5 days: 5.1%
• 1 month: 22.62%
• 3 months: 1.98%
• 6 months: 82.84%
• Year to date: -8.58%
• 1 year: 47.14%
• 5 years: -99.76%
• 10 years: -99.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Employees: 3